Clinical Pharmacology and Pain Management
Professor of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
Dr. Ma’s research interests are in examining methods that evaluate drug-drug interactions. His research has elucidated that several methods estimating in vivo, real-time, drug-metabolizing enzyme activity are inadequate and lack optimal validation. Dr. Ma is also interested in examining pain medication pharmacokinetic and pharmacodynamic variability in opioid-treated, cancer patients.
Dr. Ma's clinical practice is in pain and palliative care in an outpatient, multidisciplinary clinic at the Moores Cancer Center. Under a collaborative practice protocol, Dr. Ma sees patients and is able to start, stop, or modify therapy to treat symptoms and sides effects of a disease and its treatment.
B.S. Biology, UC Irvine (1998); Pharm.D., UC San Francisco (2002); Fellowship Clinical Pharmacology/Drug Metabolism, Bassett Healthcare, Cooperstown, NY (2002-2004).
Awards and Honors:
NIDA Intramural Research Training Award, NIH (1997, 1998); UC San Diego SSPPS Faculty Teaching Award (2008, 2013, 2017); Fellow Clinical Pharmacology, American College of Clinical Pharmacology (2015); Excellence in Achievement, American College of Clinical Pharmacology (2016).
Clinical Trial Associate, Early Development, Amgen, Inc. (2004-2007); Meeting Program Committee Member, ACCP Annual Meeting, San Antonio, TX, (2009); Co-chair, Symposium: Innovations and Controversies in Quantifying Drug-Drug Interactions, ACCP Annual Meeting, San Antonio, TX, (2009), Meeting Program Co-chair, ACCP Annual Meeting, San Diego, CA (2012).
- Pharmacogenomics (SPPS219/PHARM235)
- Pharmacy Therapeutics (SPPS 212B)
- Master’s Program in Drug Development and Product Management
- Evaluated accuracy and validity of in vivo cytochrome P450 (CYP) and P-glycoprotein phenotyping methods and probe drugs.
- Established novel course elective for pharmacy, medical, law, graduate, and business students encompassing areas of drug discovery, development, and commercialization.
- Clinical research in in vivo phenotyping studies, methodology evaluation, and utility of limited sampling strategies.
- Bordson et al. (2014). Tricyclic antidepressants: is your patient taking them? Observations on adherence and unreported use using provider- reported medication lists and urine drug testing. Pain Medicine, 15:355-363
- Ma et al. (2014). A single center, retrospective analysis evaluating the utilization of the opioid risk tool in opioid-treated cancer patients. Journal of Pain and Palliative Care Pharmacotherapy, 28:4-9
- Moy et al. (2014). Monitoring oxycodone use in patients with chronic pain: analysis of oxycodone and metabolite excretion in saliva and urine. Journal of Opioid Management, 10:47-56
- Masters et al. (2015). Limited sampling strategy of partial area under the curve to estimate midazolam systematic clearance for cytochrome P450 3A phenotyping. Ther. Drug Monit. 37:84-89
- Ma et al. (2016) Retrospective analysis of pharmacist interventions in an ambulatory palliative care practice. J. Oncol, Pharm. Pract. (6):757-765
- Experience in private and public sector in clinical
trial operations, management, and execution.
- Experience in Proof of concept, phase I (FIH), and drug-drug interaction studies.
- Developing novel teaching methods for health care professionals encompassing areas of drug discovery, development, and commercialization.